Key Points of Laboratory Diagnostics of Chronic Diffuse Liver Diseases in the Management of Patients

Hronic diffuse liver diseases (CDLDs) represent a significant global health problem due to their progressive course and high risk of complications, including cirrhosis and hepatocellular carcinoma. Timely and accurate laboratory diagnostics play a crucial role in the effective management of patients with these conditions. This abstract highlights the key laboratory parameters essential for the diagnosis, staging, and monitoring of chronic diffuse liver diseases. Core biochemical markers include serum aminotransferases (ALT, AST), alkaline phosphatase, gamma-glutamyl transferase, bilirubin fractions, and indicators of synthetic liver function such as albumin and prothrombin time. Immunological markers, viral serology, and metabolic tests contribute to etiological identification, while non-invasive fibrosis assessment tools and composite scoring systems enhance disease staging and prognosis evaluation. Regular laboratory monitoring allows assessment of disease activity, therapeutic response, and early detection of complications. Integrating laboratory findings with clinical and instrumental data ensures a comprehensive, patient-centered approach, improving outcomes and guiding personalized treatment strategies in chronic diffuse liver diseases.